Document:

Exhibit 4.9

 

Execution Version

NOMINATION RIGHTS AGREEMENT

 

This Nomination Rights Agreement is made
and entered into this 15th day of January, 2018.

 

BETWEEN:

 

OMEGA FUND IV, L.P., a limited
partnership formed under the laws of Cayman Islands (the “Investor”)

 

- and -

 

ESSA PHARMA INC., a corporation
incorporated under the laws of British Columbia (the “Corporation”)

 

WHEREAS the
Investor desires to purchase an aggregate of 20,000,000 securities comprised of a combination of Shares and pre-funded common share
purchase warrants of the Corporation (the “Investment”) as part of a larger offering of Shares and pre-funded
common share purchase warrants of the Corporation by way of a second amended and restated prospectus supplement dated January 5,
2018 to a short form base shelf prospectus dated December 22, 2015.

 

AND WHEREAS but
for the entry into of this Agreement by the Corporation, to set out certain rights the Investor will have in respect of the affairs
of the Corporation, the Investor would not make the Investment.

 

NOW THEREFORE in
consideration of the mutual covenants and agreements herein contained and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged by each of the Parties, the Parties mutually agree as follows:

 

ARTICLE 1

INTERPRETATION

 

		1.01	Definitions

 

In this Agreement, in addition to the terms
defined above, the following definitions apply:

 

		(a)	“affiliate” has the meaning ascribed to that term in the Business Corporations
Act (British Columbia);

 

		(b)	“Agreement” means this Nomination rights agreement as it may be supplemented,
amended, restated or superseded from time to time in accordance with the terms hereof;

 

		(c)	“Board” means the board of directors of the Corporation, as constituted from
time to time;

 

		(d)	“Business Day” means any day other than a Saturday or Sunday or a day that is
a statutory or bank holiday in Vancouver, British Columbia;

 

     

     

    

 

		(e)	“Effective Date” means the date of the closing of the Investment;

 

		(f)	“Exchange” means the TSX Venture Exchange, the Nasdaq Capital Market and/or
such other stock exchange that the Shares may be listed from time to time;

 

		(g)	“Management” means the management of the Corporation;

 

		(h)	“Nominating Committee” means any ad-hoc or standing committee of the Board constituted
from time to time for the purpose of making recommendations of nominees for directors to the Board or, if no such committee is
constituted, the Board; and

 

		(i)	“Shares” means common shares in the capital of the Corporation.

 

		1.02	Interpretation

 

Except as may be otherwise specifically
provided in this Agreement and unless the context otherwise requires:

 

		(a)	The
                                         terms “Agreement”, “this Agreement”, “the Agreement”,
                                         “hereto”, “hereof”, “herein”, “hereby”,
                                         “hereunder” and similar expressions refer to this Agreement in its entirety
                                         and not to any particular provision hereof.

 

		(b)	References
                                         to a “Section”, “Subsection” or “Article”
                                         followed by a number or letter refer to the specified section, subsection or article
                                         of this Agreement.

 

		(c)	Headings
                                         of sections are inserted for convenience of reference only and shall not affect
                                         the construction or interpretation of this Agreement.

 

		(d)	Unless
                                         the context otherwise requires, words importing the singular include the plural
                                         and vice versa and words importing gender include all genders.

 

		(e)	In this
                                         Agreement, a period of days shall be deemed to begin on the first day after the
                                         event which began the period and to end at 5:00 p.m. (Vancouver time) on the last day
                                         of the period. If, however, the last day of the period does not fall on a Business Day,
                                         the period shall terminate at 5:00 p.m. (Vancouver time) on the next Business Day.

 

ARTICLE 2

board nomination right

 

		2.01	Nomination Right.

 

		(a)	The Investor shall have the right to nominate one person acceptable to the Nomination Committee,
acting reasonably, to act as a director of the Corporation (the “Omega Director”), so long as the Investor owns
at least 9.99% (on an undiluted basis) of the outstanding Shares. The initial Omega Director shall be Hugo Beekman.

 

    	 	- 2 -	 

     

    

 

		(b)	If a vacancy occurs because of the death, disability, retirement, resignation or removal for any
reason of the Omega Director, the Investor may name another individual to fill such vacancy, and the Board, subject to Section
2.03, shall appoint such individual to the Board to fill the vacancy.

 

		(c)	During the term of this Agreement, the Omega Director shall, provided he or she is an independent
director within the meaning of applicable securities laws and Exchange policies and except as set forth in the proviso to Section
2.04(a), be eligible for selection in accordance with the Board’s appointment practices to serve as a member of each committee
(whether standing or special) of the Board.

 

		2.02	Corporation Obligations.

 

		(a)	The Corporation will take all necessary actions to cause and maintain, during the term of this
Agreement, the election or appointment, as applicable, of the Omega Director to the Board in accordance with the terms of this
Agreement.

 

		(b)	Without limiting the generality of Section 2.02(a), as soon as reasonably practicable following
the Effective Date, the Corporation shall, if necessary, increase the size of the Board to eight (8) members and shall appoint
the Omega Director to the Board with a term expiring at the next annual meeting of the Corporation’s shareholders. In connection
with such annual meeting and each annual meeting thereafter during the term of this Agreement, the Corporation shall nominate the
Omega Director for election as a director by the shareholders of the Corporation. In connection therewith, the Corporation shall
provide a written request to the Investor detailing all information regarding the Omega Director and the Investor required to be
included in the applicable management information circular or otherwise reasonably requested by the Corporation for inclusion therein,
together with the date upon which such information is required to be delivered to the Corporation (which date shall be not less
than 10 days following the date of such notice), and, following the Investor’s receipt of such request and on or prior to
such specified due date, the Investor shall deliver such information to the Corporation.

 

		(c)	Without limiting the generality of Section 2.02(a), following the date hereof, and for so long
as the Investor has the right to nominate the Omega Director pursuant to Section 2.01(a), the Corporation agrees to undertake all
necessary actions to assure that, with respect to each election of directors hereafter:

 

		(i)	if the Omega Director’s term has ended or will end at the date of such election, nominate
the Omega Director and include him or her in the Board’s slate of nominees and recommend and support the Omega Director for
election to the Board; and

 

		(ii)	such individual is included in any management information circular, proxy statement and/or proxy
circular prepared by the Corporation in connection with soliciting proxies for every meeting of the shareholders of the Corporation
called with respect to any election where the Omega Director’s term has ended or will end at the date of such election, and
at every adjournment or postponement thereof, and on every action or approval by written consent of the shareholders of the Corporation
or the Board with respect to such election.

 

    	 	- 3 -	 

     

    

 

		2.03	Director Qualifications.

 

		(a)	If necessary to meet the applicable independence standards of applicable securities laws and the
rules of the Exchange, the Investor will ensure that the Omega Director meets all such independence standards (including with respect
to audit and compensation committees).

 

		(b)	Notwithstanding anything herein to the contrary, the Corporation shall not be obligated to appoint,
cause to be nominated for election to the Board or recommend to the shareholders the election of any individual as a director of
the Corporation if the proposed Omega Director does not meet any eligibility criteria of general application determined or adopted
by the Nominating Committee, acting reasonably, from time to time, and the Corporation shall promptly, and, if practicable, sufficiently
in advance of any meeting of the shareholders called with respect to such election of nominees, notify the Investor of such determination
and the Investor will have the right to propose an alternate individuals to the Board until the Board has agreed to nominate an
individual so proposed for election to the Board.

 

		2.04	Status of Nominees and Indemnification. While serving on the
Board, the Omega Director shall be entitled to:

 

		(a)	all the rights and privileges of the other members of the Board, including, without limitation,
access to all notices, consents, minutes, documents, and other information and access to the Corporation’s outside advisors;
provided, however, that the Omega Director shall not be entitled to observe or participate in, and shall upon the good faith request
of the Board or any committee thereof recuse himself or herself from, any meeting or portion thereof at which the Board or any
such committee is evaluating and/or taking action with respect to i) the exercise of any of the Corporation’s rights or enforcement
of any of the obligations of the Investor under this Agreement or any other agreement to which the Investor or its affiliates is
a party, or ii) any transaction proposed by or with or affecting the Investor or its affiliates;

 

		(b)	be indemnified by the Corporation and covered by directors’ and officers’ insurance
obtained by the Corporation, at least on the same terms as other members of the Board, and the Omega Director shall agree to abide
by the written policies of the Board and committees thereof and the written policies of the Corporation applicable to members of
the Board; and

 

		(c)	enter into customary director indemnification agreements with the Corporation that will provide
for the indemnification of the Omega Director to the fullest extent permitted by applicable law.

  

    	 	- 4 -	 

     

    

 

ARTICLE 3

Voting agreement

 

		3.01	Voting Agreement

 

The Investor will vote
all Shares it holds in favour of Management’s proposals on matters of routine business (being limited to the election of
directors, the appointment of auditors, and, at the next annual meeting of shareholders only, the approval of the Corporation’s
stock option plan or grants of securities or other participations thereunder) at any meeting of the shareholders of the Corporation
held within 12 months of the Effective Date.

 

ARTICLE 4

GENERAL PROVISIONS

 

		4.01	Termination

 

The rights of the Investor
and the obligations of the Corporation set out in this Agreement shall terminate and be of no further force and effect upon the
earlier of either: (i) written agreement of the parties; or (ii) the Investor at any time owning less than 9.99% of the outstanding
Shares (on an undiluted basis). Upon the termination of this Agreement, the Investor shall, unless otherwise requested in writing
by the Corporation, use reasonable efforts to cause its Nominee to promptly resign from the Board.

 

		4.02	Further Assurances

 

Each party shall execute all such further
instruments and documents and do all such further actions as may be necessary to effectuate the documents and transactions contemplated
in this Agreement, in each case at the cost and expense of the party requesting such further instrument, document or action, unless
expressly indicated otherwise.

 

		4.03	Regulatory Approvals

 

This Agreement and the completion from
time to time of the transactions contemplated hereby are subject to receipt of all necessary regulatory approvals, including approval
of the Exchange.

 

		4.04	Registrations & Filings

 

The Investor may, in its sole discretion,
effect such registrations, recordation or other public filings as it consider necessary or desirable to evidence the rights granted
to it pursuant to this Agreement. The Investor acknowledges and agrees that the Corporation may be required to publicly file this
Agreement pursuant to applicable securities laws or Exchange policies.

 

		4.05	No Joint Venture

 

The parties agree that the transaction
contemplated hereby (or any related agreement) is not intended to create a joint venture, partnership or any other form of legal
association.

 

		4.06	Governing Law

 

This Agreement shall be governed by and
construed under the laws of the Province of British Columbia and the federal laws of Canada applicable in the Province of British
Columbia (without regard to its laws relating to any conflicts of laws). The courts of the Province of British Columbia have jurisdiction
to hear any dispute arising out of or in connection with this Agreement and the parties agree that the courts of the Province of
British Columbia are the most appropriate and convenient courts to hear any such dispute.

 

    	 	- 5 -	 

     

    

 

		4.07	Time of the Essence

 

Time is of the essence in this Agreement.

 

		4.08	Severability

 

If any provision of this Agreement is wholly
or partially invalid, this Agreement shall be interpreted as if the invalid provision had not been a part hereof so that the invalidity
shall not affect the validity of the remainder of the Agreement which shall be construed as if the Agreement had been executed
without the invalid portion. It is hereby declared to be the intention of the parties that this Agreement would have been executed
without reference to any portion which may, for any reason, hereafter be declared or held invalid.

 

		4.09	Notice

 

Any notice or other communication (in each
case, a “notice”) required or permitted to be given hereunder shall be in writing and shall be delivered by hand or
transmitted by facsimile transmission addressed to:

 

If to the Investor, to:

 

Omega Fund IV, L.P.

c/o Omega Fund Management LLC

185 Dartmouth Street, Suite 502

Boston, MA 02116

 

Attention: Hugo Beekman

Fax: [REDACTED: Personal Information.]

 

with a copy to:

 

Omega Fund Management LLC

185 Dartmouth Street, Suite 502

Boston, MA 02116

 

Attention: Anne-Mari Paster

 

If to the Corporation, to:

 

ESSA Pharma Inc.

Suite 720 - 999 West Broadway Street

Vancouver, BC V5Z 1K5

 

Attention: David Wood

Fax:  [REDACTED: Personal Information.]

 

    	 	- 6 -	 

     

    

 

with a copy to:

 

Blake, Cassels & Graydon LLP

Suite 2600 - 595 Burrard Street

Vancouver, BC V7X 1L3

 

Attn: Joseph Garcia

Fax: [REDACTED: Personal Information.]

 

Any notice given in accordance with this
section, if transmitted by facsimile transmission, shall be deemed to have been received on the next Business Day following transmission
or, if delivered by hand, shall be deemed to have been received when delivered.

 

		4.10	Amendment

 

This Agreement may not be changed, amended
or modified in any manner, except pursuant to an instrument in writing signed on behalf of each of the parties. The failure by
any party to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any such
provision unless such waiver is acknowledged in writing, nor shall such failure affect the validity of this Agreement or any part
thereof or the right of any party to enforce each and every provision. No waiver or breach of this Agreement shall be held to be
a waiver of any other or subsequent breach.

 

		4.11	Rule of Interpretation

 

The parties hereby agree that any rule
of construction to the effect that any ambiguity is to be resolved against the drafting party shall not be applicable in the interpretation
of this Agreement.

 

		4.12	Counterparts

 

This Agreement may be executed in one or
more counterparts, and by the parties in separate counterparts, each of which when executed shall be deemed to be an original,
but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature
page to this Agreement by telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

		4.13	Assignment

 

No party shall be entitled to transfer
its rights or obligations under this Agreement without the prior written consent of the other party.

 

		4.14	Third Party Beneficiaries

 

This Agreement is for the sole benefit
of the parties and their successors and permitted assigns and, except as expressly contemplated herein, nothing herein is intended
to or shall confer upon any other person any legal or equitable right, benefit or remedy of any nature or kind whatsoever under
or by reason of this Agreement.

 

    	 	- 7 -	 

     

    

 

		4.15	Entire Agreement

 

This Agreement constitute the entire agreement
between the parties with respect to the subject matter hereof and cancels and supersedes any prior understandings and agreements
between the parties with respect thereto.

 

		4.16	Effective Date

 

This agreement is effective as of the Effective
Date.

 

[The remainder of this page has been
intentionally left blank]

 

    	 	- 8 -	 

     

    

 

IN WITNESS WHEREOF the parties have executed this Agreement
as of the day and year first above written.

 

	
          
	OMEGA FUND IV, L.P., by its general partner, OMEGA FUND IV GP, L.P., by its general partner, OMEGA FUND IV GP MANAGER, LTD.

 

	 	By: 	(SIGNED) “Anne-Mari Paster”
	Name:  Anne-Mari Paster
	Title:  Managing Director, Chief Financial Officer 

 

	 	ESSA PHARMA INC.

 

	 	By:	(SIGNED) “David Wood”
	Name:  David Wood
	Title:  Chief Financial Officer

 

Signature Page – Omega Nomination
Rights AgreementExhibit 4.10

 

EXECUTION VERSION

 

AMENDED AND
RESTATED CONSULTING AGREEMENT

(2018)

 

THIS AGREEMENT made as
of this 1st day of February 2018.

 

BETWEEN:

 

MARIANNE
SADAR, an individual having an address at 4091 Bayridge Avenue, West Vancouver, British Columbia, V7V 3J9

 

(the “Consultant”)

 

AND:

 

ESSA
PHARMA INC., a corporation incorporated under the laws of the Province of British Columbia, having a registered
office at 999 West Broadway, Suite 720, Vancouver, British Columbia, V5Z 1K5

 

(the “Company”)

 

WHEREAS:

 

		A.	The Company and the Consultant entered into a consulting agreement dated December 22, 2010, as
amended by an amending agreement dated February 1, 2013 and an amending agreement dated February 1, 2015 (collectively, the “Prior
Agreement”);

 

		B.	The Company wishes to continue to retain the Consultant to provide the services hereinafter described
and the Consultant wishes to continue to provide such services to the Company; and

 

		C.	The parties have agreed to amend and restate the terms of the Prior Agreement as more fully set
out herein.

 

NOW THEREFORE, for good
and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by each Party, the Parties hereby agree
as follows:

 

		1.0	DEFINITIONS

 

1.1            In
this Agreement, the following words and expressions shall have the following meanings, unless the context otherwise requires:

 

“Agreement”
means this consulting agreement and the appendices attached hereto, as amended or supplemented from time to time.

 

“Associates”
means any of the suppliers, distributors, customers or other business partners of the Company, including BCCA and UBC.

 

     

     

    

  

“BCCA”
means the British Columbia Cancer Agency Branch or any other entity or organization by whom the Consultant may be employed at the
relevant time.

 

“Board”
means the board of directors of the Company.

 

“Business”
means the business of research, development and commercialization of therapies that relate to decreasing levels of the androgen
receptor or decreasing androgen receptor activity, including consulting to any private sector person or entity engaged in any of
the foregoing activities.

 

“CEO”
means the Chief Executive Officer of the Company.

 

“Company
Confidential Information” means Confidential Information that is owned by the Company, in whole or in part, and excludes
any Confidential Information owned by an Associate or any third party.

 

“Compensation
Committee” means a committee consisting of independent members of the Board.

 

“Confidential
Information” means trade secrets and other information, in whatever form or media, in the possession of the Company and
owned by the Company or by its Associates, which is not generally known to the public, or the nature of which is such that it would
generally be considered confidential in the industry in which the Company operates or which the Company is obligated to treat as
confidential or proprietary. Confidential Information includes the following:

 

		(a)	the Products and confidential or proprietary facts, data, techniques, biologic and other materials
and other information related to the Products or the Business of the Company;

 

		(b)	all Work Product;

 

		(c)	information regarding the Company’s business operations, methods and practices, including
market strategies, product pricing, margins and information regarding the financial, legal and corporate affairs of the Company;

 

		(d)	the names of the Company’s Associates and the nature of the Company’s relationships
with such Associates; and

 

    	 	2	 

     

    

  

		(e)	technical and business information of or regarding the Company’s Associates, including the
Associates’ technology, intellectual property, biologic and other materials, and business, but shall not include:

 

		(i)	any information that is possessed by the Consultant prior to receipt from the Company, other than
through prior disclosure by the Company, BCCA or UBC, as evidenced by the Consultant’s business records;

 

		(ii)	any information that is published or available to the general public, other than through a breach
of this Agreement or another agreement of confidentiality with the Company;

 

		(iii)	any information that is obtained by the Consultant from a third party with a valid right to disclose
it, provided that the third party is not, directly or indirectly, under an obligation of confidentiality to the Company;

 

		(iv)	any information that is disclosed by the Consultant with the prior written approval of the Company;
or

 

		(v)	any information that is required to be disclosed by operation of law or the requirement of a governmental
agency, provided that the Consultant will provide the Company with reasonable advance notice of any such proposed disclosure to
give the Company a reasonable period of time in which to object to such disclosure.

 

“Consultant’s
Fee” has the meaning ascribed thereto in Section 5.1.

 

“Effective
Date” means February 1, 2018.

 

“Excluded
Work Product” means any intellectual property that is developed, created, generated or reduced to practice by the Consultant
or any persons working in collaboration with her who are non-ESSA employees during the course of her employment with BCCA or during
the course of use of any BCCA research facilities or resources or in connection with any BCCA gift, grant or contract research
funds that pursuant to the Consultant’s employment with BCCA is the property of BCCA, unless otherwise agreed in any
agreement between BCCA, the Consultant and the Company.

 

“License
Agreement” means the Amended and Restated License Agreement between the Company, BCCA and UBC dated May 27, 2014.

 

“Parties”
means the Company and the Consultant, and “Party” means either of them.

 

    	 	3	 

     

    

  

“Products”
means:

 

		(a)	therapies, approaches, screening methodologies, diagnostic assays, therapeutic molecules, compounds
and their mechanistic action that modulate androgen receptor activity and are discovered or developed by the Company, and any other
products derived from the discovery or development by the Company of molecular compounds that can be used to treat prostate cancer;

 

		(b)	any intellectual property or assets owned, licensed, sold, marketed or used by the Company in connection
with the Business, including enhancements, modifications, additions or other improvements to such intellectual property; and

 

		(c)	any other products or technologies that the Company discovers or develops during the Term.

 

For the avoidance
of doubt, Products exclude any Excluded Work Product.

 

“Services”
means the services described in Appendix A to this Agreement.

 

“Term”
has the meaning ascribed thereto in Section 3.1.

 

“UBC”
means the University of British Columbia.

 

“Work
Product” means any and all tangible materials and any and all ideas, inventions, improvements, discoveries, know-how,
techniques, designs, developments, suggestions, products, machines, methods, hardware, names, titles, plans and works of authorship
(including computer programs, software, logic design and documentation), industrial designs, utility models and other information
and materials that relate to the Product, whether or not patentable, copyrightable or otherwise registrable under applicable statutes,
that made, conceived, created, invented, reduced to practice, developed or authored by the Consultant, either alone or jointly
with others, whether or not reduced to drawings, written description, documentation, models or other tangible form, in the course
of performing the Services hereunder (including, for the avoidance of doubt, under the Prior Agreement). For the avoidance of doubt,
Work Product excludes Excluded Work Product.

 

1.2            The
division of this Agreement into sections and the insertion of headings are for convenience of reference only and shall not affect
the construction or interpretation of this Agreement. Unless something in the subject matter or context is inconsistent therewith,
all references herein to sections or subsections are to sections or subsections of this Agreement.

 

1.3            In
this Agreement words importing the singular number only shall include the plural and vice versa, wordings importing the masculine
gender shall include the feminine and neuter genders and vice

 

    	 	4	 

     

    

  

versa and words importing
persons shall include individuals, partnerships, associations, trusts, unincorporated organizations, and companies.

 

1.4            Wherever
the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed
to be followed by the words “without limitation” and the words following “include”, “includes”
or “including” shall not be considered to set forth an exhaustive list.

 

1.5            All
references to money or currency in this Agreement are to lawful money of Canada.

 

1.6            Appendix A
and Appendix B attached hereto form an integral part of this Agreement.

 

		2.0	ENGAGEMENT OF CONSULTANT

 

2.1            The
Company hereby engages the Consultant to perform, and the Consultant hereby agrees to make herself available to perform, (i) Services
for up to 32 hours per month during the Term, at such times and place or places as the Consultant may determine, which amount of
hours of Services is based on an annual Consultant’s Fee of $180,000 CDN for the first and second years of the Term, and
(ii) Services for up to 22 hours per month during the Term, at such times and place or places as the Consultant may determine,
which amount of hours of Services is based on an annual Consultant’s Fee of $120,000 CDN for the third and fourth years of
the Term, subject to Section 5.1. Notwithstanding the foregoing, the Consultant will not be required to provide Services to the
Company for one or more vacation periods of up to two months per year, for a cumulative total of 64 hours of Services for the first
and second year of the term and 44 hours of Services for the third and fourth year of the term. Such vacation period or periods
shall be scheduled at such time or times as requested by the Consultant and approved by the CEO, such approval not to be unreasonably
withheld. For clarity, no unused annual vacation period or periods may be carried forward to a subsequent calendar year without
the authorization of the CEO.

 

2.2            The
Parties acknowledge and agree that the Consultant shall provide the Services as an independent contractor, and that this Agreement
is not intended, and will not operate, to make the Consultant an employee of the Company for any purpose whatsoever.

 

2.3            The
Consultant is solely responsible for maintaining her own insurance, including general liability and professional liability, if
applicable.

 

2.4            The
Consultant is solely responsible for maintaining her own accounting records and books.

 

2.5            The
Company acknowledges that the Consultant is an employee of BCCA and agrees that: (a) the Consultant’s employment with BCCA
is subject to the policies and requirements of BCCA, which may impose certain restrictions on her availability to perform the Services
and (b) the Consultant may, throughout the Term, continue such employment and undertake such other employment and business

    	 	5	 

     

    

  

activities as the Consultant
wishes, provided that such activities do not interfere with the performance of Services by the Consultant under this Agreement
or contravene the provisions of Section 7.0.

 

2.6            Notwithstanding
any other provision of this Agreement, the Parties acknowledge the rights of, and the Consultant’s obligations to, BCCA
that exist by virtue of the Consultant’s work with BCCA, including without limitation
with respect to Excluded Work Product, and further acknowledge that no provision of this Agreement is intended to nor will it
prevent the Consultant from fulfilling such obligations, unless otherwise agreed in any written agreement between BCCA, the Consultant
and the Company. The Consultant acknowledges that it is her sole responsibility to ensure that her provision of the Services
to the Company is in compliance with BCCA policies.

 

2.7            The
Parties recognize that any presentation by the Consultant at symposia, national or regional professional meetings, publication
in journals or other publications, accounts of the Consultant’s research with respect to the Excluded Work Product, including
research results from the Consultant’s work as an employee of BCCA, are subject to Section 10.4 and 10.5 of the License Agreement,
which the Consultant acknowledges having read and to which the Consultant agrees to be bound, and the Company and the Consultant
agree to abide by Section 10.0 of the License Agreement in respect to the Excluded Work Product. The Parties acknowledge that the
Work Product is subject to the terms of Section 6.0 of this Agreement.

 

2.8            The
Consultant will not use the name of the Company or any of its Associates in any publication or advertisement without the CEO’s
prior written approval, except this shall not apply to BCCA or any of BCCA’s Associates, save for the Consultant’s
obligation to disclose her relationship with the Company to the extent required by rules of professional conduct.

 

		3.0	TERM OF AGREEMENT

 

3.1            This
Agreement shall become effective on the Effective Date and continue in full force and effect, subject to earlier termination or
extension as hereinafter provided, for a term of four (4) years following the Effective Date (such period referred to as the “Term”).
The Term may be extended for additional periods of one year each by mutual written agreement between the Parties.

 

		4.0	duties of consultant

 

4.1            In
performing the Services, the Consultant shall act honestly and in good faith in the best interests of the Company, subject to Sections
2.5 and 2.6 of this Agreement, and shall exercise the degree of care, diligence and skill that a reasonably prudent person would
exercise in comparable circumstances.

 

4.2            The
Consultant shall report directly to the CEO.

 

    	 	6	 

     

    

 

4.3            The
Services performed by the Consultant under this Agreement will conform to and will be carried out in accordance with such lawful
written directives or guidelines as may be prescribed from time to time by the CEO, subject to Sections 2.5 and 2.6 of this Agreement,
and where such directives have not been prescribed, the Consultant is authorized to exercise her independent judgment in the furtherance
of the Company’s best interests, based on the information made available to her by the Company, and consistent with such
lawful general instructions as have been prescribed by the CEO.

 

4.4            The
Consultant represents that the performance of the Services in accordance with this Agreement will not breach any agreement by which
the Consultant is bound, including without limitation any agreement limiting the use or disclosure of proprietary information acquired
by the Consultant in confidence prior to the Consultant’s engagement as a consultant to the Company. The Consultant further
represents and agrees that the Services performed hereunder will not be conducted in a manner that would conflict with her obligations
to third parties, including BCCA. The Consultant hereby represents and warrants to the Company that as of the date hereof neither
the execution nor the delivery of this Agreement will constitute or result in the breach of or default under any terms, provisions
or conditions of, or conflict with or violate, any contract to which the Consultant is a party or is subject to or by which the
Consultant is bound or from which the Consultant derives benefit.

 

		5.0	compensation

 

5.1            The
Company will pay to the Consultant an annual fee as compensation for the performance by the Consultant of the Services hereunder
(the “Consultant’s Fee”). For the first and second year of the Term, the Consultant’s Fee shall
be of $180,000 CDN, which shall be paid in equal monthly installments of $15,000 each, in accordance with Section 5.6, commencing
on February 1, 2018. For the third and fourth year of the Term, the Consultant’s Fee shall be $120,000 CDN, which
shall be paid in equal monthly installments of $10,000 each, in accordance with Section 5.6, commencing on February 1, 2020 and
February 1, 2021, respectively. However, in the event that the Consultant’s provision of Services is expected to involve
greater hours than anticipated in Section 2.1 herein, at least 60 days prior to the commencement of the third and fourth year of
the Term, the Company and the Consultant shall negotiate in good faith for the purposes of increasing the amount of compensation
payable to the Consultant for the following year, such compensation to be based upon a mutually agreed upon work plan, setting
out the scope of the Services for the following year.

 

5.2            At
the end of each year of the Term of this Agreement, the Company may pay a bonus of up to 25% of the Consultant’s Fee (the
“Bonus”) to Consultant upon accomplishment of certain Consultant objectives, which align with Company goals.
Payment of any Bonus is at the recommendation of the Compensation Committee and at the sole discretion of the Board of Directors
of the Company. The Consultant objectives, which shall align with Company goals, will be as determined by the Company in consultation
with its Compensation Committee and agreed to by the Consultant prior to the beginning of each year of the Term. The Consultant
objectives and the associated quantum and timing of payment of the Bonus for the first year of the Term are listed in Appendix
B of this Agreement.

 

    	 	7	 

     

    

 

5.3            Throughout
the Term, the Company will reimburse the Consultant for all actual, reasonable and approved expenses incurred by the Consultant
in the course of her performance of the Services, including air and automobile travel, meals and lodging for business trips and
other out of pocket expenses, provided that the Consultant provides evidence of such expenses.

 

5.4            The
Company will not make any statutory deductions from any payments to the Consultant, since the Consultant is not and will not be
an employee of the Company. The Consultant agrees that the Company is not responsible for any statutory deductions or withholdings
from payments to the Consultant, including but not limited to deductions or withholdings related to Income Tax, Workers’
Compensation, Employment Insurance and Canada Pension Plan.

 

5.5            The
Consultant agrees to indemnify the Company from any claims, charges, taxes, penalties or demands which may be made by the Minister
of National Revenue or other statutory body against the Company for failure to make statutory deductions from invoices submitted
by the Consultant, including but not limited to, Income Tax, Workers’ Compensation, Employment Insurance and Canada Pension
Plan.

 

5.6            Subject
to Section 5.2, all fees paid to the Consultant under this Agreement, plus applicable provincial and federal taxes thereon, will
be payable monthly in arrears, by cash or cheque, within 30 business days of the end of the relevant month. The Consultant
shall from time to time provide invoices as may be reasonably requested by the Company.

 

5.7            All
expenses to be paid to the Consultant under this Agreement will be payable within 15 business days after a written request
from the Consultant for reimbursement, including supporting receipts.

 

5.8            The
Consultant shall be entitled to participate in incentive plans, to extent eligible under the terms of each such plan, established
from time to time by the Board. The terms of any such participation shall be determined by the Board, or a compensation committee
thereof, in its discretion.

 

5.9            The
Consultant will not be entitled to participate in any medical, dental, extended health or group life insurance plans of the Company
or any other benefits available to employees of the Company.

 

5.10          In
recognition of past services and contributions to the Company, on February 21, 2018 the Company shall grant to the Consultant
options to acquire 1,600,000 common shares of the Company (pre 1:20 share consolidation) at an exercise price of $0.245 CDN/share
(pre 1:20 share consolidation), such exercise price not being less than the closing market price of the Company’s common
shares on the day prior to the granting of the options. If there is any consolidation, subdivision or reclassification of the
common shares of the Company, the number of shares subject to the options under this Section shall be adjusted accordingly. Such
options shall vest monthly in arrears, in accordance with the terms of the Company’s stock option plan (the “Stock
Option Plan”) in 48 equal installments, with the first installment vesting on the one month anniversary of the date
of the grant, being March 21, 2018, and

 

    	 	8	 

     

    

  

subsequent installments vesting every one month
anniversary thereafter. Vested options shall be exercisable at any time and from time to time by the Consultant or her personal
representative giving written notice to the Company of the number of vested options the Consultant or personal representative is
exercising, and delivering payment to the Company of the corresponding exercise price, with such options being exercisable up to
5:00 p.m. local time in Vancouver, British Columbia on the expiry date in accordance with the terms of the Stock Option Plan. The
stock options may continue to vest beyond the Term of this agreement as stated in Section 3.0. Notwithstanding the foregoing, any
of the options which have not yet vested will vest immediately upon the occurrence of any of the following events:

 

		(a)	the direct or indirect acquisition or conversion of more than 50% of the issued and
                                                              outstanding shares of the Company by a person or group of persons acting in concert, other than through an employee share
                                                              purchase plan or employee share ownership plan and other than by persons who are or who are controlled by, the existing
                                                              shareholders of the Company;

 

		(b)	a merger, amalgamation or arrangement of the Company or of the voting shares of the Company
                                                              where the voting shares of the resulting merged, amalgamated or arranged company, as applicable, are owned or controlled by
                                                              shareholders of whom more than 50% are not the same as the shareholders of the Company immediately prior to the merger,
                                                              amalgamation or arrangement;

 

		(c)	a sale by the Company of greater than 50% of the fair market value of the assets of the Company,
through one or a series of transactions, to an entity that is not controlled by either the shareholders of the Company or by the
Company; or

 

		(d)	the death or Disability (as such term is defined in the Stock Option Plan) of the Consultant.

 

For greater certainty, the options granted
in this Section 5.10 are subject to the terms of the Stock Option Plan, and in the event of any conflict between the terms of this
Agreement and the Stock Option Plan, or the certificate representing such options, the terms of the Stock Option Plan and option
certificate shall govern.

 

		6.0	CONFIDENTIALITY AND INTELLECTUAL
PROPERTY

 

6.1            The
Consultant acknowledges that the Company Confidential Information consists entirely of trade secrets, confidential and
proprietary information that is the exclusive property of the Company or Associates from whom the Company has obtained its
rights. At all times during the Term and for a period of five years after the termination or expiry of this Agreement,
or in the case of trade secrets for so long as the information qualifies as trade secrets, the Consultant will treat the
Company Confidential Information in strict confidence and will not, directly or indirectly, disclose, allow access to,
transmit or transfer the Confidential Information to a third party (other than the Company’s or any Associate’s
directors, officers, bankers, consultants, business collaborators or partners, licensors, sublicensees,

 

    	 	9	 

     

    

  

suppliers, distributors,
agents and legal and financial advisors in the ordinary course of business and on a reasonable need to know basis) unless otherwise
required by law or by a regulatory authority having jurisdiction over the Company, or except as previously approved in writing
by the Company. The Consultant will protect such Company Confidential Information from disclosure by exercising a standard of care
as may reasonably be expected to preserve its secret and confidential nature. The Consultant acknowledges and agrees that nothing
contained in this Agreement will be construed as an assignment to the Consultant of any right, title or interest in the Company
Confidential Information. As between the Company and the Consultant, all right, title and interest relating to the Company Confidential
Information is expressly reserved by the Company and the Associates from whom the Company has obtained its rights. All documents
containing Confidential Information are the property of the Company or the relevant Associate.

 

6.2            At
all times during the Term and for a period of five years after the termination or expiry of this Agreement, or in the case
of trade secrets for so long as the information qualifies as trade secrets, the Consultant will not use any of the Company Confidential
Information in any manner except as reasonably required for the Consultant to provide the Services. Without limiting the generality
of the foregoing, the Consultant agrees that at all times during and subsequent to the consulting relationship, the Consultant
will not use or take advantage of the Company Confidential Information for creating, maintaining or marketing, or aiding in the
creation, maintenance or marketing, of any product that is competitive with any of the Products.

 

6.3            The
Consultant will not copy or reproduce the Company Confidential Information except in the course of the Consultant’s consulting
relationship with and for the benefit of the Company or with the written approval of the Company. All copies of Company Confidential
Information remain the property of the Company.

 

6.4            Nothing
in this Agreement precludes the Company from obtaining, protecting or enforcing its intellectual property rights or enforcing the
Consultant’s obligations pursuant to the provisions of Section 6.0 or Section 7.0 in a court of competent jurisdiction,
or from pursuing any other remedy available to it for such breach or threatened breach, including the recovery of damages from
the Consultant. The Consultant acknowledges that irreparable harm may result to the Company if the Consultant breaches the Consultant’s
obligations under Section 6.0 or Section 7.0. The Consultant acknowledges that such a breach may not properly be compensated
by an award of damages. Accordingly, the remedy for any such breach may include, in addition to other available remedies and damages,
injunctive relief or other equitable relief enjoining such breach at the earliest possible date, and the Company will be entitled
to seek injunctive relief restraining the Consultant from breaching any of the provisions of Sections 6.0 and 7.0.

 

6.5            The
Consultant agrees to make full disclosure to the Company of each Work Product promptly after its creation. The Consultant hereby
assigns and transfers, and agrees to assign and transfer as they arise, to the Company, and agrees that the Company will be the
exclusive owner of, any and all rights,

 

    	 	10	 

     

    

  

title
and interests that the Consultant may have in and to each Work Product (including for more clarity those Work Product created prior
to the Effective Date in connection with the Business) throughout the world, including all trade secrets, patent rights, copyrights
and all other intellectual property rights therein. The Consultant further agrees to cooperate fully at all times during and subsequent
to the Term with respect to signing further documents and doing such acts and other things reasonably requested by the Company,
at the Company’s expense, to confirm such transfer of ownership of rights, including intellectual property rights, effective
at or after the time the Work Product is created and to enable the Company to apply for, obtain, and enforce patents or copyrights
or other rights or protections relating to the Work Product in any and all countries. The Consultant agrees that the obligations
in this Section 6.5 will continue beyond the termination of this Agreement with respect to any and all Work Product made,
conceived, created, invented, developed, acquired or reduced to practice prior to or during the Term. For purposes of the copyright
laws of the United States of America, to the extent, if any, that such laws are applicable to any Work Product, the Work Product
will be considered a work made for hire and the Company will be considered the author thereof. Should the Consultant for any reason
fail to provide the Company with the assistance required by this Section 6.5, then the Consultant hereby irrevocably designates
the CEO as the agent and attorney-in-fact of the Consultant to execute and file any such documents and to do all lawful acts necessary
to apply for and obtain patents, copyrights and other protections, and to enforce the Company’s rights under this Section 6.5.
The Consultant will not receive any further consideration in respect of post-termination assistance provided to the Company, provided
that the expense of obtaining or enforcing intellectual property protection, including the reasonable expenses of the Consultant,
will be borne by Company. Notwithstanding anything contrary in the foregoing, the parties acknowledge that the provisions
of this Section 6.5 are subject to the Consultant’s obligations set forth in Sections 2.5 and 2.6 of this Agreement and the
terms of the License Agreement. For the avoidance of doubt, the obligations under this subsection 6.5 do not apply to Excluded
Work Product.

 

6.6            The
Consultant agrees that the Company, its assignees and their respective licensees are not required to designate the Consultant as
the author of any Work Product. The Consultant hereby waives in whole all moral rights that the Consultant may have in any Work
Product, including the right to the integrity of the Work Product, the right to be associated with the Work Product, the right
to restrain or claim damages for any distortion, mutilation or other modification of the Work Product, and the right to restrain
use or reproduction of the Work Product in any context and in connection with any product, service, cause or institution.

 

		7.0	RESTRICTIONS

 

7.1            The
Consultant agrees that, at all times during this Agreement and for a period of 3 months after the termination of this Agreement
if this Agreement is terminated by the Company pursuant to Section 8.1(a) hereto, or is terminated by the Consultant pursuant to
Section 8.2 hereto, she will not:

 

    	 	11	 

     

    

 

7.1.1            either
individually or in conjunction with any person, as principal, agent, director, officer, employee, investor or in any other manner
whatsoever, directly or indirectly, engage in or become financially interested in a competitive Business anywhere in North
America, the United Kingdom, the European Union and/or Japan without the prior written consent of the Company; provided that the
foregoing will not prevent the Consultant from holding any class of shares of a public company, partnership or other organization,
provided that the Consultant, alone or in conjunction with any other person, will not directly or indirectly hold more than 10%
of the shares of any such company; for greater certainty, BCCA is not considered to be a competitive Business for the purposes
of this Subsection.

 

7.2            The
Consultant agrees that, at all times during this Agreement and for a period of 12 months after the expiry or termination of
this Agreement in accordance with the terms hereof (regardless of which Party terminates this Agreement and regardless of the reason
for such termination, if any), she will not:

 

7.2.1            either
directly or indirectly, on the Consultant’s own behalf or on behalf of others, solicit, divert or hire away, or attempt to
solicit, divert, or hire away, any person employed by the Company or persuade or attempt to persuade any such individual to terminate
his or her employment with the Company; provided, however, this provision shall not apply where a person has responded to an advertisement
of general notice for employment; and

 

7.2.2            directly
or indirectly impair or seek to impair any relationships that the Company has with its employees, consultants, customers, suppliers,
licensors, sublicensees, distributors, agents or other parties with which the Company does business or has contractual relations.

 

		8.0	TERMINATION

 

8.1            The
Company may terminate this Agreement, by giving notice thereof to the Consultant:

 

		a.	if the Consultant is, at any time during the Term, convicted of an indictable offence which:

 

		i.	involves fraud or dishonesty; or

 

		ii.	affects the Consultant's ability to provide the Services;

 

		b.	if the Consultant fails
to make herself available to perform Services in accordance with Section 2.1 (other than by reason of death, disability,
illness or vacation, or due to the provisions of Sections 2.5 or 2.6) for a period of not less than two consecutive months
and if such failure continues thereafter for a period of not less than 30 days after the Company gives notice to the Consultant
advising of the Consultant’s failure to perform

 

    	 	12	 

     

    

  

Services for such
two month period and requesting the Consultant to perform Services within the 30-day period following such notice;

 

or

 

		c.	any other fundamental breach of this Agreement including, without limitation, Section 7.1.1 hereto.

 

8.2            The
Consultant may, at any time, give 120 calendar days advance written notice to the Company of the Consultant’s
intention to terminate this Agreement and on the expiration of such period this Agreement will be terminated. Such notice period
may be adjusted upon mutual agreement and may expire on any day of the month and the Consultant’s Fee payable hereunder will
be proportioned to the date of such termination.

 

8.3            This
Agreement will terminate forthwith on the death or Disability of the Consultant.

 

8.4            Other
than the payment of the Consultant’s Fee, the reimbursement of reasonable expenses as provided for in Section 5.0,
the payment of awarded Bonuses, and the vesting of options described in Section 5.10, there will be no fees or other payments of
any kind payable to the Consultant upon the termination of this Agreement. For greater certainty, the options described in Section
5.10 may continue to be exercisable following the termination of this Agreement, in accordance with the terms of the certificate
representing such options and the Stock Option Plan.

 

8.5            Upon
termination of this Agreement, the Consultant will return to the Company all property of the Company which is then in the Consultant’s
possession or under her control, including all written information, tapes, discs, memory devices or other material in any medium
pertaining to the Services and all Company Confidential Information, without retaining copies or records of any Company Confidential
Information whatsoever.

 

		9.0	GENERAL

 

9.1            No
failure by either Party to exercise any right or remedy in respect of this Agreement will operate as a waiver thereof, unless
it is in writing and signed by such Party. Unless expressly provided for therein, such waiver will not limit or affect the rights
of either Party with respect to any other or subsequent breach of the same or any other provision.

 

9.2            Any
notice or direction required or permitted to be given under this Agreement shall be in writing and may be given by mailing
the same by registered or certified mail or delivering the same addressed to the Party at the address first above written, or to
such other address as a Party may specify by notice to the other and shall be deemed to have been given, if delivered, on the date
of delivery if it is a business day, and otherwise on the next succeeding business day and, if mailed, on the fifth business

 

    	 	13	 

     

    

  

day
following the posting of the notice except if there is a postal dispute, in which case all communications shall be delivered.

 

9.3            This
Agreement will not be construed as creating a partnership, joint venture or agency relationship between the Parties or any other
form of legal association that would impose liability upon one Party for any act or failure to act by the other Party.

 

9.4            This
Agreement states and comprises the entire agreement between the Parties in connection with the subject matter hereof and cancels
and supersedes all previous correspondence, negotiations, promises, agreements, covenants, conditions, representations and
warranties with respect to the subject matter herein. There are no representations, warranties, terms, conditions, undertakings
or collateral agreements express or implied between the Parties other than expressly set forth in this Agreement.

 

9.5            The
Parties agree that this Agreement is personal in nature and may not be assigned or otherwise transferred by either of the
Parties, nor may any right or obligation hereunder be assigned or transferred directly or indirectly by either of the Parties,
whether voluntarily, by operation of law or otherwise, without the written consent of the other Party.

 

9.6            This
Agreement shall be governed and construed in accordance with the laws of the Province of British Columbia and federal laws of Canada
applicable therein. The Parties hereby attorn to the exclusive jurisdiction of the Courts of the Province of British Columbia.

 

9.7            No
alteration or amendment of this Agreement shall take effect unless the same is in writing duly executed by the Parties.

 

9.8            If
any one or more of the provisions contained in this Agreement shall be determined to be invalid, illegal or unenforceable, the
remaining provisions contained herein shall not in any way be affected or impaired thereby.

 

9.9            The
Consultant acknowledges and agrees that she has had the opportunity to seek independent legal advice in relation to the nature,
contents, terms and effect of this Agreement and the Consultant voluntarily accepted the consideration provided by the Company
for the purpose of entering into this Agreement.

 

9.10          This
Agreement shall enure to the benefit of and be binding upon the Parties and their respective heirs, executors, administrators,
successors and permitted assigns.

 

9.11          This
Agreement may be executed in counterparts, and such original executed counterparts together shall constitute one agreement.

 

IN WITNESS WHEREOF this
Agreement has been executed by the Parties as of the date and year first above written.

 

    	 	14	 

     

    

  

	SIGNED, SEALED AND DELIVERED in the presence of:	 	 	 
	 	 	 	 
	 	 	 	 
	Signature	 	 	 
	 	 	 	 
	675 West 10th Avenue, Vancouver, BC	 	 	 
	Address	 	 	 
	 	 	 	 
	Administrative Coordinator	 	 	(SIGNED) “Marianne Sadar”
	Occupation	 	 	MARIANNE SADAR, Consultant
	 	 	 	 

 

ESSA PHARMA INC.

 

	Per: 	(SIGNED) “David R. Parkinson”	 
	 	David R. Parkinson, CEO	 

  

    	 	15	 

     

    

 

Appendix
A

 

SERVICES
to be Performed by the consultant

 

The Services to be performed
by the Consultant under the Consulting Agreement to which this Appendix A is attached shall consist of the following:

 

		1.	Participating in the development of Work Product for
the Company

 

		2.	Participating in the assessment and review of business and scientific matters, including participation
in any Scientific or Medical Advisory Board as the Company may constitute, and as the Company may request

 

		3.	Assisting in the development of scientific and business strategies and presentations for the Company

 

		4.	Assisting the Company in preparing regulatory submissions relating to the Product

 

		5.	Assisting the Company with respect to patent protection

 

		6.	Reviewing scientific literature relating to the Product

 

    	 	A-1	 

     

    

 

Appendix
B

 

objectives
and bonus payments applicable through this agreement

 

The annual bonus may represent up to 25% of
the amount of this Agreement, the actual amount to be determined by the Compensation Committee in consideration of the contributions
of the Consultant and commensurate with the financial status of the Company.

 

For Calendar 2018, the amount of the bonus
will be decided on the basis of contributions to the business objectives and strategic objectives of the company, specifically
Consultant’s contribution toward enabling the Company to achieve its annual goals as established by the Compensation Committee
and approved by the Board of Directors. Consistent with the Consultant’s scientific and other contributions, considerations
will include assessment of the services performed by the Consultant as outlined in Appendix A. These services will serve the following
major initiatives:

 

		1.	Support towards identifying, characterizing, and advancing the next generation compounds to IND
filing, including the activities outlined in Appendix A

 

		2.	Support towards strengthening ESSA external interactions and messaging through preclinical collaborations,
relevant publications, interactions with investors and potential industrial partners

 

    	 	B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]